GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 10, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares, sec-filing
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 10, 2025, that it repurchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing details a transaction in the company's own shares, indicating a potential share buyback program.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report on share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker for share repurchase
- October 2025 (date) — Reporting period
- 001-15170 (other) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on a transaction in GSK plc's own shares, specifically the purchase of ordinary shares by the company through its broker.
Who is acting as the broker for GSK's share repurchase?
BNP Paribas SA is acting as the broker for GSK plc in the purchase of the company's ordinary shares.
What type of shares did GSK plc purchase?
GSK plc purchased its own ordinary shares of 31¼ pence.
What is the filing date and reporting period for this document?
The filing date is October 10, 2025, and the reporting period is for the month of October 2025.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 3,062 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-10 06:10:41
Filing Documents
- a8130c.htm (6-K) — 1765KB
- 0001654954-25-011629.txt ( ) — 1766KB
From the Filing
IN OWN SHARES a8130c     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 09 October 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 295,000 Lowest price paid per share (GBp): 1,628.00p Highest price paid per share (GBp): 1,647.50p Volume-weighted average price paid per share (GBp): 1,640.23p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 2,549,000 ordinary shares.   Following the above purchase, the Company will hold 250,013,844 ordinary shares in treasury and have 4,065,394,695 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,065,394,695. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.15 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases   Shares purchased:   GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:   09 October 2025   Investment firm:      BNP Paribas SA     Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   30,077   1,647.50p   1,633.50p   1,640.30p   CHIX   47,705   1,646.50p   1,633.50p   1,641.00p   XLON   217,218   1,647.50p   1,628.00p   1,640.05p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   269   1628.0   XLON   09-Oct-2025   08:00:36   20251009147124919   395   1628.0   XLON   09-Oct-2025   08:01:02   20251009147125181   343   1629.5   XLON   09-Oct-2025   08:01:40   20251009147125875   544   1629.5   XLON   09-Oct-2025   08:01:51   20251009147126058